An Open-Label Protocol for the Use of Uridine Triacetate as an Antidote to Treat Patients at Excess Risk of 5-Fluorouracil Toxicity Due to Overdosage or Impaired Elimination

Trial Profile

An Open-Label Protocol for the Use of Uridine Triacetate as an Antidote to Treat Patients at Excess Risk of 5-Fluorouracil Toxicity Due to Overdosage or Impaired Elimination

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 13 Sep 2016

At a glance

  • Drugs Uridine triacetate (Primary)
  • Indications Poisoning
  • Focus Expanded access; Therapeutic Use
  • Sponsors Wellstat Therapeutics Corporation
  • Most Recent Events

    • 13 Sep 2016 Results of this and other study assessing safety and efficacy of uridine triacetate for the prevention and treatment of 5-fluorouracil and capecitabine toxicity published in the Cancer.
    • 07 Jun 2016 Results of this and other study presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results of this and other study presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top